Niquitin Minilozenge (Nicotine)

Niquitin Minilozenge, a nicotine replacement therapy, is used to aid smoking cessation by addressing nicotine dependence.

• Smoking cessation: assists adult smokers in quitting by alleviating cravings and withdrawal symptoms.
• Relapse prevention: supports individuals who have quit to maintain abstinence and avoid relapse.
• Nicotine dependence: provides a controlled nicotine source to reduce the physiological drive for tobacco use.

• Nicotine in the lozenge acts as an agonist at nicotinic acetylcholine receptors in the central nervous system, partially stimulating these receptors and thereby diminishing the intensity of withdrawal symptoms and cravings associated with abrupt cessation of tobacco smoking.

Niquitin Minilozenge may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Mouth irritation or soreness: mild discomfort in the oral cavity.
• Hiccups: brief, involuntary diaphragmatic contractions.
• Nausea or upset stomach: occasional digestive upset.
• Increased salivation: excess saliva production.
• Throat irritation: scratchy feeling in the throat.

Serious or Rare Side Effects

• Allergic reaction: rash, itching, swelling, or difficulty breathing.
• Chest pain or palpitations: unusual cardiac sensations.
• Severe mouth ulceration: persistent ulcer that does not heal.
• Anaphylaxis: rare, life‑threatening systemic allergic response.
• Arrhythmia: irregular heart rhythm requiring medical attention.

Before using Niquitin Minilozenge, consider the following safety measures.

• Assess nicotine dependence: evaluate the level of tobacco use to select appropriate therapy.
• Medical guidance: use under the supervision of a qualified healthcare professional.
• Contraindication: avoid if known hypersensitivity to nicotine or any excipients.
• Cardiovascular caution: use with care in patients with recent heart disease or uncontrolled hypertension.
• Not for non‑smokers: avoid use in individuals who do not use tobacco products.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Niquitin Minilozenge can interact with other substances that affect nicotine metabolism or cardiovascular function.

Major Interactions (Avoid)

• Concurrent nicotine products: using other nicotine replacement therapies or tobacco can lead to excess nicotine exposure.
• Monoamine oxidase inhibitors (MAOIs): may increase the risk of hypertensive episodes.

Moderate Interactions (Monitor Closely)

• Caffeine: nicotine may enhance stimulant effects, leading to jitteriness.
• Warfarin: nicotine can alter anticoagulant control; monitor INR.
• Antipsychotics (e.g., clozapine): nicotine may affect plasma levels; adjust dosing if needed.
• Beta‑blockers: nicotine may increase heart rate, requiring closer cardiovascular monitoring.